Veracyte director Jens Holstein sells at $50 a share

Q: How many VCYT shares did director Jens Holstein sell?

Jens Holstein sold 7,500 shares at $47.00 per share on September 24, 2026, and 7,500 shares at $50.00 per share on October 27, 2026. On each date, he also exercised options for 7,500 shares at $35.30 per share under a Rule 10b5-1 plan adopted June 12, 2026.

Both option exercises and sales were made under a Rule 10b5-1 plan adopted on June 12, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Veracyte, Inc. (VCYT) director Jens Holstein exercised options for 7,500 common shares on September 24, 2026, at an exercise price of $35.30 per share, and sold 7,500 shares at $47.00 per share. On October 27, 2026, he exercised another 7,500 options at $35.30 per share and sold 7,500 shares at $50.00 per share. The transactions were made pursuant to a Rule 10b5-1 plan adopted June 12, 2026. The September 24 transactions were not timely reported due to an inadvertent administrative error not attributable to Holstein.

Insider Trade Summary 10b5-1

Exercise and Sale: 15,000 shares ($198K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Holstein Jens

Role Director

Sold 15,000 shs ($728K)

Approx. gross sale proceeds $728K

Approx. exercise cost $530K

Approx. pre-tax spread $198K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) ^{F1, F3}	7,500	$0.00	$0.00
Exercise	Common Stock ^F1	7,500	$35.30	$265K
Sale	Common Stock ^F1	7,500	$50.00	$375K
Exercise	Stock Option (right to buy) ^{F1, F2, F3}	7,500	$0.00	$0.00
Exercise	Common Stock ^{F1, F2}	7,500	$35.30	$265K
Sale	Common Stock ^{F1, F2}	7,500	$47.00	$353K

Holdings After Transaction: Stock Option (right to buy) — 20,000 contracts (Direct); Common Stock — 27,471 shares (Direct)

Footnotes (3)

F1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2026.
F2. The transaction reported on this line was not timely reported due to an inadvertent administrative error not attributable to the reporting person.
F3. The option is fully vested.

Key Figures

Shares acquired through option exercise: 7,500 shares Exercise price: $35.30 per share Shares sold: 7,500 shares +4 more

7 metrics

Shares acquired through option exercise 7,500 shares September 24, 2026

Exercise price $35.30 per share Options exercised September 24, 2026

Shares sold 7,500 shares September 24, 2026

Sale price $47.00 per share September 24, 2026

Shares acquired through option exercise 7,500 shares October 27, 2026

Shares sold 7,500 shares October 27, 2026

Sale price $50.00 per share October 27, 2026

Key Terms

Rule 10b5-1 plan, exercise price, Stock Option (right to buy), fully vested

4 terms

Rule 10b5-1 plan regulatory

"made pursuant to a Rule 10b5-1 plan adopted"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

exercise price financial

"at an exercise price of $35.30 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Stock Option (right to buy) financial

"Stock Option (right to buy)"

fully vested financial

"The option is fully vested."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many VCYT shares did director Jens Holstein sell?

Jens Holstein sold 7,500 shares at $47.00 per share on September 24, 2026, and 7,500 shares at $50.00 per share on October 27, 2026. On each date, he also exercised options for 7,500 shares at $35.30 per share under a Rule 10b5-1 plan adopted June 12, 2026.

Why was Jens Holstein’s September 2026 VCYT transaction reported late?

The September 24, 2026 transaction was not timely reported due to an inadvertent administrative error not attributable to the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/28/2026 - 04:06 PM EDT Accepted by SEC EDGAR 10/28/2026 - 04:05 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Holstein Jens

(Last)

(First)

(Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/24/2026		M⁽¹⁾⁽²⁾		7,500	A	$35.3	34,971	D
Common Stock	09/24/2026		S⁽¹⁾⁽²⁾		7,500	D	$47	27,471	D
Common Stock	10/27/2026		M⁽¹⁾		7,500	A	$35.3	34,971	D
Common Stock	10/27/2026		S⁽¹⁾		7,500	D	$50	27,471	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$35.3	09/24/2026		M⁽¹⁾⁽²⁾			7,500	⁽³⁾	08/01/2030	Common Stock	7,500	$0	27,500	D
Stock Option (right to buy)	$35.3	10/27/2026		M⁽¹⁾			7,500	⁽³⁾	08/01/2030	Common Stock	7,500	$0	20,000	D

Explanation of Responses:

1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2026.

2. The transaction reported on this line was not timely reported due to an inadvertent administrative error not attributable to the reporting person.

3. The option is fully vested.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	10/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR